Welcome to the July 2017 edition of our newsletter, Updates on Myeloproliferative Neoplasms. This edition provides articles on such topics as evaluation for CML in the setting of unexplained leukocytosis and thrombocytosis in MPNs, risks and benefits of antithrombotic therapy in essential thrombocythemia, and administration of direct oral anticoagulants in patients with myeloproliferative neoplasms.
This month I'd like to highlight Chapter 2 of the expert video roundtable I moderated, as it discusses the most common BCR/ABL-negative MPNs.
Please share this newsletter with your colleagues and don’t hesitate to get in touch with me with your comments or suggestions through the editors of the Journal of the Advanced Practitioner in Oncology, or JADPRO, at email@example.com at any time.
Until next time, take a look at the links I’ve gathered for you here. I hope you find this newsletter to be a useful resource in your practice.
Lindsey Lyle, MS, PA-C
University of Colorado, Anschutz Medical Campus